←
PCF Science10,899 posts
PCF Science avatar

PCF Science

@PCF_Science

The official Twitter account for scientific news from the Prostate Cancer Foundation. Follow us at @PCFNews @ PCF-science.bsky.social

◷ Joined October 2016▧ 1,209 Photos and videos
Neeraj Agarwal, MD, FASCO avatar
⟳ PCF Science retweeted
Neeraj Agarwal, MD, FASCO@neerajaiims·Oct 26

Just happened today👏🎉👉 @FDA approved Talazoparib + enzalutamide for pts with HRRm positive mAPMS/mHSPC #prostatecancer FDA Link👉 l1nq.com/ltlq6jk 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @DanaFarber_GU

Post attachmentPost attachmentPost attachmentPost attachment

Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

Post attachmentPost attachmentPost attachmentPost attachment
Toni Choueiri, MD avatar
⟳ PCF Science retweeted
Toni Choueiri, MD@DrChoueiri·Oct 24

Superb presentation by Georgina Long! INTerpath-001: adding personalized mRNA vaccine intismeran to pembrolizumab reduced recurrence/death risk by 42% in resected stage IIB-IV melanoma (HR 0.58). A major step for cancer vaccines! #ESMO26 @OncoAlert @myESMO #ESMO26

Post attachmentPost attachment
Toni Choueiri, MD avatar
⟳ PCF Science retweeted
Toni Choueiri, MD@DrChoueiri·Oct 23

Encouraging OS results in neuroendocrine prostate cancer at #ESMO26! #KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone. • mOS: 10.2 vs 7.1 months (HR 0.33) • rPFS: 5.1 vs 4.0 months (HR 0.66) • PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16) No new safety signals observed. @myESMO @oncoalert

Post attachmentPost attachmentPost attachmentPost attachment
Ali Arafa avatar
⟳ PCF Science retweeted
Ali Arafa@aliarafaa·Oct 19

Thank you, @EAntonarakis ! Truly honored and grateful to @PCF_Science and the Milken Family Foundation. Thank you for your mentorship, alongside Justin Hwang and @DrJustinDrake , and to the patients who make this work possible. Excited for what's ahead! @UMNCancer

Congrats to our newest PCF Young Investigator from Minnesota, the one-and-only Dr. Ali Arafa @aliarafaa. @UMNCancer @UMNews @ThePCCTC @PCF_Science

Post attachmentPost attachmentPost attachmentPost attachment
Michael Hofman avatar
⟳ PCF Science retweeted
Michael Hofman@DrMHofman·Oct 19

Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26 @EANM_NucMed Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025). So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles: - Remarkably well tolerated: just 1 grade 3 toxicity (anaemia) - PSA50 response 75%, PSA90 response 33% - Median PSA-PFS and rPFS not reached The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway. Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC @pros_tic team who made this investigator-initiated trial possible. Grateful to @Isotopia_Global and the for their support #TOP (Top Rated Oral Presentation)

Adam B. Weiner, MD avatar
⟳ PCF Science retweeted
Adam B. Weiner, MD@Adam_Weiner535·Oct 22

🚨 Focal salvage HDR brachy for radiorecurrent #prostatecancer🚨 📜@JCO_ASCO 👥 n=62, intraprostatic radiorecurrence after prior RT, multi-institutional 📊 Phase 1/2, dose-escalated focal salvage HDR, up to 30 Gy in 1 to 2 fractions ⏱️ Median f/u 39.4 mo ✅ No acute grade 3 toxicity; late grade 3 in 2 pts (3.2%) ✅ 3-yr bPFS 62.7%, MFS 85.9% ✅ Higher Decipher GC score tracked w/ worse bPFS, rPFS, MFS; all 4 pts w/ GC >0.85 recurred ⚠️ Small GC subset (n=31), single-arm, hypothesis-generating 🎯 Focal salvage HDR is well tolerated & a genomic classifier may prognosticate 🔗 doi.org/10.1200/JCO-25-02730 @UroOnc @urotoday @UrologyTimes @PCF_Science @Davicioni

Post attachmentPost attachmentPost attachment
Neeraj Agarwal, MD, FASCO avatar
⟳ PCF Science retweeted
Neeraj Agarwal, MD, FASCO@neerajaiims·Oct 13

Exciting opportunity for Urology & med onc trainees and practicing physicians👉Elevate your clinical and leadership skills at the @PCFnews Leadership Academy! 📍Santa Monica | Dec 3–5, 2026 ✅ Expert faculty mentoring ✅ Formal certification ✅ Travel & hotel covered 👉Apply: bit.ly/4dyRWlv @urotoday

Post attachment
Salma Kaochar avatar
⟳ PCF Science retweeted
Salma Kaochar@Kaochar2·Oct 12

Not all prostate cancers follow the same molecular playbook! 🧬 🚨🚨Excited to share our new work in @CellReports, spearheaded by graduate student @RizwanKinza 👏and medical student Sai Manikonda👏, revealing distinct genomic alterations and transcriptional programs associated with SPOP-mutant prostate cancer. Another step toward more biologically informed precision oncology! @BCMFromtheLabs Above all, grateful to the patients who generously contributed their biospecimens to advance cancer research. 💕 A heartfelt thank you to our collaborators for their hard work, support, and invaluable feedback throughout this journey. @CCoarfa @marthamims And a special shout-out to the often-unsung heroes of science—our reviewers! Their thoughtful and constructive feedback made this a stronger manuscript. 💕 Proud of this team and grateful for the support of @BCMDeptMedicine @bcmhouston, @PCF_Science, CDMRP PCRP and @NIH @theNCI 🔗cell.com/cell-reports/fullte…

Hsieh Lab avatar
⟳ PCF Science retweeted
Hsieh Lab@HsiehLab·Oct 7

Of note, @yeonsookim_phd (@theNCI K99/R00 awardee) is on the academic job market, so keep an eye out for her. She is an outstanding RNA and cancer biologist!

Hsieh Lab avatar
⟳ PCF Science retweeted
Hsieh Lab@HsiehLab·Oct 7

Ever wonder if tRNAs can regulate the identity of a cancer cell? @HsiehLab @FredHutch postdoc @yeonsookim_phd did and discovered a single tRNA that can control lineage dependency and drug sensitivity in prostate cancer published today @Nature: nature.com/articles/s41586-0…

CRIS Cancer Foundation avatar
⟳ PCF Science retweeted
CRIS Cancer Foundation@CRISCANCERUK·Oct 8

What an inspiring few days at the Prostate Cancer Foundation Annual Scientific Retreat! 🔬🌍 We were so proud to present two new CRIS Cancer–PCF Young Investigator Awards to Kirsty Hodgson (Newcastle University) and Nicolás Anselmino (VHIO). 🏆 #ProstateCancer

Post attachment
Tyler Seibert MD PhD avatar
⟳ PCF Science retweeted
Tyler Seibert MD PhD@TylerSbrt·Oct 10

ARIEL trial: 📄 and🧵on MRI🧲 changes with RT+ADT for #ProstateCancer 👇🏼 @OncoAlert @UroToday @imagingprostate @ASTRO_org @PCF_science @MedwatchHQ #practicalRO #ASTRO26 @adornisch_MD @DrRanaMcKay @medmund14 @UCSDRadMed @DrTylerStewart @UCSDCancer

New in #practicalRO: Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) Trial: Protocol, Early Results, and Implications of Neoadjuvant ADT for Focal RT Boost in Prostate Cancer. This article was presented during #ASTRO2026 in Quick Pitch Session 22.

Post attachment